The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...

Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...

The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer. Pembrolizumab (Keytruda) and berahyaluronidase alfa ...

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients. The use of bispecific ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...